| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 51 | 2025 | 395 | 5.980 |
Why?
|
| Neuromyelitis Optica | 5 | 2025 | 34 | 2.610 |
Why?
|
| Pyridazines | 14 | 2022 | 49 | 2.250 |
Why?
|
| Imidazoles | 14 | 2022 | 219 | 1.960 |
Why?
|
| Protein Kinase Inhibitors | 19 | 2025 | 633 | 1.850 |
Why?
|
| Sirolimus | 16 | 2013 | 230 | 1.660 |
Why?
|
| Drug Resistance, Neoplasm | 13 | 2025 | 821 | 1.610 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 6 | 2016 | 145 | 1.460 |
Why?
|
| Pyrimidines | 11 | 2025 | 446 | 1.310 |
Why?
|
| TOR Serine-Threonine Kinases | 11 | 2013 | 429 | 1.260 |
Why?
|
| Antineoplastic Agents | 15 | 2022 | 1826 | 1.220 |
Why?
|
| Organophosphorus Compounds | 5 | 2025 | 25 | 1.090 |
Why?
|
| Interferon-beta | 13 | 2013 | 56 | 0.950 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 6 | 2013 | 48 | 0.890 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2025 | 357 | 0.870 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 | 2018 | 103 | 0.860 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2016 | 1011 | 0.820 |
Why?
|
| Fusion Proteins, bcr-abl | 11 | 2020 | 43 | 0.790 |
Why?
|
| Myelin Basic Protein | 19 | 2011 | 67 | 0.680 |
Why?
|
| Cell Line, Tumor | 19 | 2018 | 3748 | 0.660 |
Why?
|
| Endometrial Neoplasms | 2 | 2013 | 110 | 0.660 |
Why?
|
| Mutation | 18 | 2025 | 6099 | 0.620 |
Why?
|
| Lung Neoplasms | 6 | 2025 | 1545 | 0.610 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2022 | 22 | 0.600 |
Why?
|
| Latin America | 6 | 2024 | 110 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2022 | 61 | 0.550 |
Why?
|
| Humans | 124 | 2026 | 131163 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2016 | 1336 | 0.550 |
Why?
|
| Adjuvants, Immunologic | 5 | 2010 | 393 | 0.530 |
Why?
|
| Arthritis, Juvenile | 1 | 2018 | 45 | 0.520 |
Why?
|
| Rural Health Services | 1 | 2018 | 41 | 0.510 |
Why?
|
| T-Lymphocytes | 20 | 2011 | 1722 | 0.500 |
Why?
|
| Medical Marijuana | 1 | 2016 | 6 | 0.490 |
Why?
|
| Marijuana Smoking | 1 | 2016 | 30 | 0.480 |
Why?
|
| Cannabis | 1 | 2016 | 50 | 0.470 |
Why?
|
| Immunologic Factors | 3 | 2011 | 190 | 0.470 |
Why?
|
| Philadelphia Chromosome | 4 | 2020 | 41 | 0.460 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 3 | 2013 | 21 | 0.460 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 169 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2016 | 1618 | 0.440 |
Why?
|
| Piperazines | 5 | 2014 | 265 | 0.440 |
Why?
|
| Central Nervous System | 2 | 2016 | 269 | 0.440 |
Why?
|
| Sarcoma | 3 | 2012 | 219 | 0.440 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 707 | 0.420 |
Why?
|
| Pyridines | 2 | 2016 | 255 | 0.420 |
Why?
|
| Neoplasms | 8 | 2015 | 3016 | 0.420 |
Why?
|
| Mitoxantrone | 2 | 2013 | 28 | 0.410 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2011 | 123 | 0.400 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2025 | 35 | 0.390 |
Why?
|
| Pyrazoles | 2 | 2016 | 349 | 0.380 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2013 | 37 | 0.380 |
Why?
|
| Central America | 2 | 2025 | 22 | 0.380 |
Why?
|
| Caribbean Region | 2 | 2025 | 20 | 0.380 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2019 | 25 | 0.380 |
Why?
|
| Gene Expression Regulation | 8 | 2007 | 2323 | 0.370 |
Why?
|
| Lymphocyte Activation | 5 | 2011 | 633 | 0.360 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2012 | 354 | 0.360 |
Why?
|
| Imatinib Mesylate | 6 | 2016 | 47 | 0.350 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2012 | 57 | 0.350 |
Why?
|
| Female | 62 | 2026 | 70963 | 0.350 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 712 | 0.340 |
Why?
|
| Leukemia | 3 | 2023 | 387 | 0.340 |
Why?
|
| Telemedicine | 1 | 2018 | 526 | 0.340 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 34 | 0.330 |
Why?
|
| Benzamides | 6 | 2015 | 127 | 0.330 |
Why?
|
| Immunosuppressive Agents | 8 | 2013 | 663 | 0.330 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 66 | 0.320 |
Why?
|
| Mice, Nude | 6 | 2016 | 700 | 0.320 |
Why?
|
| Hematologic Neoplasms | 2 | 2011 | 315 | 0.310 |
Why?
|
| Phosphorylation | 7 | 2012 | 1571 | 0.310 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2012 | 219 | 0.310 |
Why?
|
| Mice, SCID | 6 | 2016 | 585 | 0.300 |
Why?
|
| Dependovirus | 3 | 2007 | 160 | 0.280 |
Why?
|
| Adult | 49 | 2026 | 31282 | 0.280 |
Why?
|
| Autoimmune Diseases | 2 | 2001 | 262 | 0.280 |
Why?
|
| Mice | 18 | 2016 | 18301 | 0.270 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 689 | 0.270 |
Why?
|
| Animals | 23 | 2016 | 33912 | 0.270 |
Why?
|
| Biological Products | 1 | 2010 | 145 | 0.270 |
Why?
|
| Male | 53 | 2026 | 64957 | 0.260 |
Why?
|
| Middle Aged | 44 | 2026 | 28601 | 0.250 |
Why?
|
| Scleroderma, Systemic | 1 | 2008 | 118 | 0.250 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2008 | 167 | 0.240 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 428 | 0.240 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2006 | 10 | 0.240 |
Why?
|
| Vaccines | 1 | 2011 | 388 | 0.240 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2026 | 34 | 0.240 |
Why?
|
| Enzyme Inhibitors | 4 | 2016 | 573 | 0.240 |
Why?
|
| Gene Transfer Techniques | 3 | 2007 | 344 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 981 | 0.230 |
Why?
|
| Aged | 30 | 2026 | 21025 | 0.230 |
Why?
|
| Unconsciousness | 1 | 2005 | 27 | 0.230 |
Why?
|
| Circulating Tumor DNA | 2 | 2025 | 45 | 0.230 |
Why?
|
| Consensus | 2 | 2025 | 512 | 0.230 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2020 | 895 | 0.220 |
Why?
|
| Cell Line | 15 | 2012 | 2552 | 0.220 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2019 | 229 | 0.220 |
Why?
|
| Benzhydryl Compounds | 1 | 2005 | 79 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 614 | 0.210 |
Why?
|
| Central Nervous System Stimulants | 1 | 2005 | 133 | 0.210 |
Why?
|
| Registries | 4 | 2024 | 1634 | 0.210 |
Why?
|
| Erythropoietin | 1 | 2004 | 102 | 0.200 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1419 | 0.200 |
Why?
|
| Indoles | 2 | 2015 | 200 | 0.200 |
Why?
|
| Postoperative Hemorrhage | 1 | 2024 | 83 | 0.200 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2024 | 103 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2016 | 2465 | 0.190 |
Why?
|
| Postoperative Complications | 5 | 2005 | 3147 | 0.190 |
Why?
|
| Cell Growth Processes | 3 | 2011 | 62 | 0.190 |
Why?
|
| Peptide Fragments | 9 | 2004 | 687 | 0.190 |
Why?
|
| Tumor Burden | 2 | 2014 | 240 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2013 | 59 | 0.180 |
Why?
|
| Human Growth Hormone | 2 | 2000 | 74 | 0.180 |
Why?
|
| Autoantibodies | 3 | 2021 | 451 | 0.180 |
Why?
|
| Drug Synergism | 2 | 2013 | 237 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2020 | 14 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2000 | 688 | 0.180 |
Why?
|
| Immunophilins | 6 | 2000 | 10 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 4 | 2016 | 978 | 0.170 |
Why?
|
| Aquaporin 4 | 1 | 2021 | 16 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1272 | 0.170 |
Why?
|
| Protein Binding | 4 | 2015 | 1652 | 0.170 |
Why?
|
| Interferon beta-1a | 6 | 2010 | 23 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2011 | 325 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2010 | 3763 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2016 | 265 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2013 | 4686 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2012 | 252 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2009 | 3436 | 0.150 |
Why?
|
| Attitude | 1 | 2020 | 111 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2001 | 333 | 0.150 |
Why?
|
| Apoptosis | 6 | 2012 | 1827 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 165 | 0.150 |
Why?
|
| Treatment Outcome | 11 | 2016 | 12936 | 0.150 |
Why?
|
| Peptides | 7 | 2013 | 708 | 0.140 |
Why?
|
| Ovarian Reserve | 1 | 2019 | 15 | 0.140 |
Why?
|
| Endoplasmic Reticulum | 1 | 2000 | 208 | 0.140 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 6797 | 0.140 |
Why?
|
| Models, Molecular | 5 | 2014 | 1064 | 0.140 |
Why?
|
| Mexico | 2 | 2016 | 190 | 0.140 |
Why?
|
| Genetic Techniques | 1 | 1999 | 95 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2021 | 282 | 0.140 |
Why?
|
| Time Factors | 8 | 2018 | 6196 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 2003 | 59 | 0.140 |
Why?
|
| Chile | 1 | 2018 | 25 | 0.140 |
Why?
|
| Molecular Conformation | 2 | 2016 | 96 | 0.140 |
Why?
|
| Genetic Vectors | 5 | 2007 | 892 | 0.140 |
Why?
|
| Herpesvirus 6, Human | 3 | 2003 | 53 | 0.130 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2014 | 83 | 0.130 |
Why?
|
| Prevalence | 2 | 2018 | 2701 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2018 | 276 | 0.130 |
Why?
|
| U937 Cells | 1 | 2016 | 22 | 0.120 |
Why?
|
| Social Conditions | 1 | 2016 | 4 | 0.120 |
Why?
|
| Brain | 4 | 2006 | 3175 | 0.120 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 18 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 83 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2018 | 174 | 0.120 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 44 | 0.120 |
Why?
|
| Phosphines | 1 | 2016 | 2 | 0.120 |
Why?
|
| Snake Venoms | 2 | 2010 | 4 | 0.120 |
Why?
|
| Sulfones | 1 | 2016 | 72 | 0.120 |
Why?
|
| Pyridones | 2 | 2015 | 140 | 0.120 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2015 | 11 | 0.120 |
Why?
|
| South America | 2 | 2026 | 45 | 0.120 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 33 | 0.120 |
Why?
|
| Cytokines | 9 | 2003 | 1339 | 0.110 |
Why?
|
| Enzyme Precursors | 1 | 1995 | 22 | 0.110 |
Why?
|
| Autoantigens | 3 | 2004 | 97 | 0.110 |
Why?
|
| Drug Administration Schedule | 6 | 2012 | 732 | 0.110 |
Why?
|
| Vaccination | 4 | 2002 | 1060 | 0.110 |
Why?
|
| Hospitals | 1 | 2018 | 435 | 0.110 |
Why?
|
| Th2 Cells | 3 | 2000 | 188 | 0.110 |
Why?
|
| Reperfusion | 1 | 1994 | 26 | 0.110 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1994 | 33 | 0.110 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 323 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2016 | 179 | 0.110 |
Why?
|
| Mast Cells | 1 | 1995 | 68 | 0.110 |
Why?
|
| Immunodominant Epitopes | 3 | 1999 | 45 | 0.110 |
Why?
|
| Young Adult | 8 | 2020 | 10103 | 0.110 |
Why?
|
| Administration, Oral | 4 | 2016 | 711 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 386 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2010 | 588 | 0.100 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1994 | 79 | 0.100 |
Why?
|
| Structure-Activity Relationship | 6 | 2016 | 552 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2018 | 730 | 0.100 |
Why?
|
| Aortic Aneurysm | 3 | 1991 | 225 | 0.100 |
Why?
|
| Cell Survival | 2 | 2016 | 826 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 5 | 2012 | 179 | 0.100 |
Why?
|
| Drainage | 2 | 1994 | 250 | 0.100 |
Why?
|
| Injections, Subcutaneous | 3 | 2010 | 136 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.100 |
Why?
|
| Immunoblotting | 2 | 2012 | 292 | 0.100 |
Why?
|
| Pyrroles | 1 | 2014 | 188 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 59 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 6 | 2000 | 975 | 0.090 |
Why?
|
| Antibodies, Anti-Idiotypic | 3 | 2003 | 40 | 0.090 |
Why?
|
| Tacrolimus | 3 | 2003 | 100 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 512 | 0.090 |
Why?
|
| Transfection | 3 | 2015 | 962 | 0.090 |
Why?
|
| Tosyl Compounds | 1 | 2012 | 22 | 0.090 |
Why?
|
| Phosphoproteins | 2 | 2012 | 448 | 0.090 |
Why?
|
| Glatiramer Acetate | 4 | 2013 | 17 | 0.090 |
Why?
|
| Roseolovirus Infections | 2 | 2003 | 29 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2012 | 619 | 0.090 |
Why?
|
| Ribosomal Protein S6 | 1 | 2012 | 14 | 0.090 |
Why?
|
| Anilides | 1 | 2012 | 52 | 0.090 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2012 | 40 | 0.090 |
Why?
|
| Exons | 1 | 2014 | 759 | 0.090 |
Why?
|
| Injections, Intramuscular | 2 | 2004 | 185 | 0.090 |
Why?
|
| Genes, abl | 1 | 2011 | 6 | 0.090 |
Why?
|
| Incidence | 3 | 2024 | 3360 | 0.090 |
Why?
|
| Natalizumab | 1 | 2011 | 5 | 0.090 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2011 | 18 | 0.090 |
Why?
|
| Skin | 2 | 2012 | 545 | 0.090 |
Why?
|
| Nitriles | 1 | 2012 | 163 | 0.090 |
Why?
|
| Toluene | 1 | 2011 | 10 | 0.090 |
Why?
|
| Adolescent | 10 | 2018 | 20987 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 224 | 0.080 |
Why?
|
| Dimerization | 6 | 2003 | 137 | 0.080 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 32 | 0.080 |
Why?
|
| G1 Phase | 1 | 2011 | 68 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 26 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2012 | 219 | 0.080 |
Why?
|
| INDEL Mutation | 1 | 2011 | 93 | 0.080 |
Why?
|
| HCT116 Cells | 1 | 2011 | 65 | 0.080 |
Why?
|
| Alkynes | 1 | 2011 | 27 | 0.080 |
Why?
|
| Tacrolimus Binding Proteins | 6 | 2000 | 68 | 0.080 |
Why?
|
| Aniline Compounds | 1 | 2011 | 27 | 0.080 |
Why?
|
| Macrophage Inflammatory Proteins | 2 | 2001 | 10 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2011 | 594 | 0.080 |
Why?
|
| Receptors, CCR5 | 2 | 2001 | 30 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2016 | 546 | 0.080 |
Why?
|
| Colubridae | 1 | 2010 | 1 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2011 | 67 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2012 | 423 | 0.080 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 775 | 0.080 |
Why?
|
| Kinetics | 4 | 2000 | 1088 | 0.080 |
Why?
|
| Random Allocation | 1 | 2011 | 409 | 0.080 |
Why?
|
| Chemokine CCL5 | 2 | 2001 | 53 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2003 | 193 | 0.080 |
Why?
|
| Cerebrospinal Fluid | 1 | 1991 | 99 | 0.080 |
Why?
|
| Paraplegia | 1 | 1991 | 84 | 0.080 |
Why?
|
| Snake Bites | 1 | 2010 | 17 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 1994 | 395 | 0.080 |
Why?
|
| Therapeutic Equivalency | 1 | 2010 | 16 | 0.080 |
Why?
|
| Ligands | 3 | 2000 | 481 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 710 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 2001 | 786 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 4066 | 0.080 |
Why?
|
| Crystallography, X-Ray | 4 | 2013 | 364 | 0.080 |
Why?
|
| Golgi Apparatus | 2 | 2000 | 92 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 227 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 1994 | 372 | 0.080 |
Why?
|
| Drug Approval | 1 | 2010 | 48 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2026 | 17753 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2013 | 407 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2019 | 787 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2009 | 130 | 0.070 |
Why?
|
| Prognosis | 6 | 2018 | 4886 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 408 | 0.070 |
Why?
|
| Clone Cells | 7 | 2004 | 153 | 0.070 |
Why?
|
| Thrombosis | 1 | 2013 | 499 | 0.070 |
Why?
|
| Genetic Therapy | 2 | 2007 | 713 | 0.070 |
Why?
|
| Sex Factors | 2 | 2011 | 1356 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 4738 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2065 | 0.070 |
Why?
|
| Europe | 2 | 2024 | 365 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2014 | 4697 | 0.070 |
Why?
|
| Molecular Sequence Data | 9 | 2004 | 3464 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5196 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2011 | 523 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 1173 | 0.060 |
Why?
|
| Rats | 4 | 2016 | 3370 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2004 | 1205 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 570 | 0.060 |
Why?
|
| Complementarity Determining Regions | 2 | 2004 | 26 | 0.060 |
Why?
|
| Glioma | 1 | 2011 | 494 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 475 | 0.060 |
Why?
|
| Glucose | 1 | 2011 | 853 | 0.060 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2006 | 15 | 0.060 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 1994 | 699 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 905 | 0.060 |
Why?
|
| Pentobarbital | 1 | 1986 | 21 | 0.060 |
Why?
|
| Hypoxia, Brain | 1 | 1986 | 34 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2008 | 312 | 0.060 |
Why?
|
| Narcolepsy | 1 | 1986 | 9 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2010 | 525 | 0.060 |
Why?
|
| Glioma, Subependymal | 1 | 2005 | 1 | 0.060 |
Why?
|
| Japan | 1 | 2026 | 161 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2004 | 272 | 0.060 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2005 | 14 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 134 | 0.060 |
Why?
|
| United Kingdom | 1 | 2026 | 267 | 0.060 |
Why?
|
| Cells, Cultured | 7 | 2004 | 2885 | 0.060 |
Why?
|
| Monocytes | 2 | 2004 | 335 | 0.050 |
Why?
|
| Anticonvulsants | 2 | 2006 | 363 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 1267 | 0.050 |
Why?
|
| Australasia | 1 | 2024 | 5 | 0.050 |
Why?
|
| Molecular Mimicry | 2 | 2003 | 17 | 0.050 |
Why?
|
| Survival Rate | 3 | 2018 | 2114 | 0.050 |
Why?
|
| Serotyping | 1 | 2004 | 170 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2004 | 57 | 0.050 |
Why?
|
| Amino Acid Sequence | 7 | 2002 | 2395 | 0.050 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2004 | 2 | 0.050 |
Why?
|
| Myelin Proteolipid Protein | 2 | 2001 | 28 | 0.050 |
Why?
|
| Phenytoin | 1 | 2004 | 54 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 1999 | 126 | 0.050 |
Why?
|
| Oligonucleotide Probes | 1 | 2004 | 84 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 315 | 0.050 |
Why?
|
| North America | 1 | 2024 | 255 | 0.050 |
Why?
|
| Bradycardia | 1 | 2004 | 58 | 0.050 |
Why?
|
| Adoptive Transfer | 2 | 2002 | 235 | 0.050 |
Why?
|
| Duodenum | 1 | 2024 | 111 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 1986 | 266 | 0.050 |
Why?
|
| Cross-Linking Reagents | 1 | 2003 | 47 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2023 | 32 | 0.050 |
Why?
|
| Internet | 1 | 2006 | 420 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 265 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2016 | 114 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 150 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 259 | 0.050 |
Why?
|
| Ophthalmoplegia | 1 | 2003 | 52 | 0.050 |
Why?
|
| Protein Engineering | 2 | 2000 | 61 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2025 | 236 | 0.050 |
Why?
|
| Research | 2 | 2021 | 264 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2004 | 504 | 0.050 |
Why?
|
| Cell Movement | 3 | 2002 | 876 | 0.050 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2003 | 82 | 0.050 |
Why?
|
| Autoimmunity | 2 | 2001 | 175 | 0.050 |
Why?
|
| Viral Proteins | 2 | 2002 | 337 | 0.050 |
Why?
|
| DNA, Recombinant | 2 | 1999 | 71 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2004 | 639 | 0.050 |
Why?
|
| Proteins | 2 | 1998 | 1006 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2002 | 440 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 587 | 0.050 |
Why?
|
| Virus Diseases | 2 | 2001 | 285 | 0.050 |
Why?
|
| Th1 Cells | 2 | 2000 | 158 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 15 | 0.050 |
Why?
|
| Estriol | 1 | 2002 | 12 | 0.050 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 2 | 1999 | 6 | 0.040 |
Why?
|
| I-kappa B Proteins | 1 | 2002 | 36 | 0.040 |
Why?
|
| Immunophenotyping | 4 | 2004 | 332 | 0.040 |
Why?
|
| Risk Factors | 2 | 2013 | 11074 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 2002 | 96 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2002 | 131 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 889 | 0.040 |
Why?
|
| Antibodies, Viral | 3 | 2003 | 1176 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1378 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2002 | 68 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2006 | 1240 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2004 | 439 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2018 | 15110 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 511 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 108 | 0.040 |
Why?
|
| Interferon beta-1b | 1 | 2001 | 3 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 1071 | 0.040 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2000 | 19 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2003 | 463 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 1981 | 94 | 0.040 |
Why?
|
| Gadolinium DTPA | 1 | 2001 | 46 | 0.040 |
Why?
|
| Body Water | 1 | 2001 | 87 | 0.040 |
Why?
|
| Phosphotyrosine | 2 | 2004 | 30 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2002 | 448 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 2001 | 110 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2002 | 346 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2004 | 552 | 0.040 |
Why?
|
| Intracellular Membranes | 1 | 2000 | 54 | 0.040 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2000 | 73 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 2000 | 47 | 0.040 |
Why?
|
| Evoked Potentials | 1 | 2001 | 113 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2004 | 697 | 0.040 |
Why?
|
| Retroviridae | 1 | 2000 | 182 | 0.040 |
Why?
|
| Furin | 1 | 2000 | 6 | 0.040 |
Why?
|
| Proinsulin | 1 | 2000 | 13 | 0.040 |
Why?
|
| Subtilisins | 1 | 2000 | 11 | 0.040 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1999 | 6 | 0.040 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 1999 | 11 | 0.040 |
Why?
|
| Heart Failure | 1 | 2013 | 2332 | 0.040 |
Why?
|
| Neurotoxins | 1 | 1980 | 44 | 0.040 |
Why?
|
| Myoclonus | 1 | 1979 | 31 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 716 | 0.040 |
Why?
|
| Genotype | 1 | 2005 | 2595 | 0.040 |
Why?
|
| Premenopause | 1 | 2019 | 33 | 0.040 |
Why?
|
| Spinal Cord | 2 | 1990 | 255 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1882 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2013 | 260 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2000 | 137 | 0.040 |
Why?
|
| Child | 2 | 2018 | 26341 | 0.040 |
Why?
|
| HLA-DR2 Antigen | 1 | 1998 | 3 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2009 | 239 | 0.040 |
Why?
|
| Carboxylic Acids | 1 | 1998 | 19 | 0.040 |
Why?
|
| Muscular Atrophy | 1 | 1979 | 84 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2000 | 224 | 0.030 |
Why?
|
| Amino Acid Substitution | 2 | 2015 | 405 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1999 | 341 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2005 | 1106 | 0.030 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2019 | 46 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 1980 | 161 | 0.030 |
Why?
|
| Urination Disorders | 1 | 1998 | 14 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2018 | 47 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2000 | 993 | 0.030 |
Why?
|
| Lymphocyte Count | 3 | 2004 | 118 | 0.030 |
Why?
|
| United States | 2 | 2026 | 12072 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 132 | 0.030 |
Why?
|
| Base Sequence | 3 | 2011 | 2730 | 0.030 |
Why?
|
| Contrast Media | 1 | 2001 | 474 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1801 | 0.030 |
Why?
|
| Safety | 1 | 2018 | 215 | 0.030 |
Why?
|
| Cell Division | 3 | 2004 | 718 | 0.030 |
Why?
|
| Ischemia | 2 | 1990 | 359 | 0.030 |
Why?
|
| Adenoviridae | 1 | 1999 | 579 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2002 | 807 | 0.030 |
Why?
|
| Piperidines | 1 | 1998 | 223 | 0.030 |
Why?
|
| Aorta, Abdominal | 3 | 1991 | 96 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 597 | 0.030 |
Why?
|
| Spinal Cord Injuries | 1 | 1999 | 273 | 0.030 |
Why?
|
| Protein Conformation | 2 | 2013 | 732 | 0.030 |
Why?
|
| Drug Interactions | 2 | 2009 | 237 | 0.030 |
Why?
|
| Models, Genetic | 1 | 1999 | 749 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 1363 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3359 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2015 | 69 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 201 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 66 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2000 | 1117 | 0.030 |
Why?
|
| Leukemia, Basophilic, Acute | 1 | 1995 | 4 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2016 | 291 | 0.030 |
Why?
|
| Leukotrienes | 1 | 1995 | 6 | 0.030 |
Why?
|
| Receptors, IgE | 1 | 1995 | 11 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2015 | 75 | 0.030 |
Why?
|
| Syk Kinase | 1 | 1995 | 17 | 0.030 |
Why?
|
| Vaccinia virus | 1 | 1995 | 50 | 0.030 |
Why?
|
| Insulin | 1 | 2000 | 1149 | 0.030 |
Why?
|
| Constriction | 1 | 1994 | 46 | 0.030 |
Why?
|
| Tyrosine | 1 | 1995 | 142 | 0.030 |
Why?
|
| Epitopes | 3 | 2001 | 324 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 387 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 357 | 0.030 |
Why?
|
| Interleukins | 1 | 1995 | 122 | 0.030 |
Why?
|
| Interleukin-10 | 3 | 2000 | 192 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 2049 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 491 | 0.030 |
Why?
|
| Disease Progression | 3 | 2006 | 2200 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 1994 | 123 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 400 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 801 | 0.020 |
Why?
|
| Amylases | 1 | 2012 | 20 | 0.020 |
Why?
|
| Interferon-gamma | 3 | 2000 | 544 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1994 | 761 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 58 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1995 | 450 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 1692 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 3385 | 0.020 |
Why?
|
| Lipase | 1 | 2012 | 91 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1994 | 294 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2013 | 161 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2013 | 142 | 0.020 |
Why?
|
| Drosophila | 1 | 2016 | 739 | 0.020 |
Why?
|
| Glycolysis | 1 | 2013 | 174 | 0.020 |
Why?
|
| Prospective Studies | 2 | 1994 | 6459 | 0.020 |
Why?
|
| Aorta, Thoracic | 3 | 1991 | 530 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2004 | 2550 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 223 | 0.020 |
Why?
|
| Cell Separation | 2 | 2004 | 218 | 0.020 |
Why?
|
| Cyclization | 1 | 2011 | 16 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2012 | 139 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 680 | 0.020 |
Why?
|
| Antibody Formation | 2 | 2002 | 227 | 0.020 |
Why?
|
| Quality of Life | 1 | 2021 | 2082 | 0.020 |
Why?
|
| Fluoroimmunoassay | 1 | 2010 | 5 | 0.020 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 1991 | 17 | 0.020 |
Why?
|
| Chemokine CCL4 | 2 | 2001 | 13 | 0.020 |
Why?
|
| Chemokine CCL3 | 2 | 2001 | 17 | 0.020 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2010 | 1 | 0.020 |
Why?
|
| Granulation Tissue | 1 | 2010 | 12 | 0.020 |
Why?
|
| Thymidine Phosphorylase | 1 | 2010 | 11 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 1129 | 0.020 |
Why?
|
| Thymidylate Synthase | 1 | 2010 | 20 | 0.020 |
Why?
|
| First Aid | 1 | 2010 | 3 | 0.020 |
Why?
|
| Capecitabine | 1 | 2010 | 20 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 1991 | 52 | 0.020 |
Why?
|
| Ecchymosis | 1 | 2010 | 11 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 282 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2010 | 54 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2011 | 5063 | 0.020 |
Why?
|
| Finger Injuries | 1 | 2010 | 18 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 531 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 80 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2011 | 315 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 130 | 0.020 |
Why?
|
| Cross Reactions | 2 | 2003 | 158 | 0.020 |
Why?
|
| Interleukin-4 | 2 | 2000 | 144 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 108 | 0.020 |
Why?
|
| Edema | 1 | 2010 | 130 | 0.020 |
Why?
|
| Analgesics | 1 | 2010 | 120 | 0.020 |
Why?
|
| Catheterization | 1 | 1991 | 226 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 153 | 0.020 |
Why?
|
| DNA-Binding Proteins | 3 | 2004 | 1939 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 1287 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 195 | 0.020 |
Why?
|
| fas Receptor | 2 | 1999 | 40 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 780 | 0.020 |
Why?
|
| Alanine | 2 | 1999 | 160 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2000 | 808 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1591 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1216 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2004 | 502 | 0.020 |
Why?
|
| Stem Cells | 2 | 2004 | 702 | 0.020 |
Why?
|
| Pain | 1 | 2010 | 450 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 304 | 0.020 |
Why?
|
| Angiostatins | 1 | 2007 | 3 | 0.020 |
Why?
|
| Prealbumin | 1 | 2007 | 27 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 53 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 1239 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 1319 | 0.020 |
Why?
|
| Anesthesia, Intravenous | 1 | 1986 | 7 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1986 | 24 | 0.020 |
Why?
|
| Raphe Nuclei | 1 | 1986 | 16 | 0.020 |
Why?
|
| Paresis | 1 | 2006 | 32 | 0.020 |
Why?
|
| JC Virus | 1 | 2006 | 26 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 1986 | 46 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2006 | 57 | 0.010 |
Why?
|
| Pons | 1 | 1986 | 34 | 0.010 |
Why?
|
| International Cooperation | 1 | 2006 | 165 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2015 | 2406 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2006 | 76 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1986 | 241 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 224 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 351 | 0.010 |
Why?
|
| Neurology | 1 | 2006 | 116 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 1013 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2004 | 31 | 0.010 |
Why?
|
| Anti-Retroviral Agents | 1 | 2006 | 155 | 0.010 |
Why?
|
| K562 Cells | 1 | 2004 | 97 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 130 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 242 | 0.010 |
Why?
|
| Milk Proteins | 1 | 2004 | 95 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 71 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2004 | 110 | 0.010 |
Why?
|
| STAT5 Transcription Factor | 1 | 2004 | 93 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2004 | 191 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1986 | 301 | 0.010 |
Why?
|
| Infrared Rays | 1 | 2003 | 19 | 0.010 |
Why?
|
| Saccades | 1 | 2003 | 20 | 0.010 |
Why?
|
| Organic Chemicals | 1 | 2003 | 58 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 2003 | 45 | 0.010 |
Why?
|
| Videotape Recording | 1 | 2003 | 54 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2003 | 66 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2004 | 109 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1586 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 1207 | 0.010 |
Why?
|
| Gadolinium | 1 | 2003 | 110 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2007 | 371 | 0.010 |
Why?
|
| Observer Variation | 1 | 2003 | 311 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1680 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2002 | 32 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 1224 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2004 | 410 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 556 | 0.010 |
Why?
|
| Virion | 1 | 2002 | 115 | 0.010 |
Why?
|
| Amino Acids | 1 | 2004 | 566 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2002 | 135 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 210 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1981 | 129 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 992 | 0.010 |
Why?
|
| Erythroid Precursor Cells | 1 | 2000 | 19 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 2000 | 44 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2000 | 62 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 117 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 148 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 159 | 0.010 |
Why?
|
| Microtomy | 1 | 2000 | 4 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1489 | 0.010 |
Why?
|
| Seizures | 1 | 2006 | 890 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 38 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 164 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2002 | 217 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2000 | 9 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 500 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2000 | 142 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2000 | 150 | 0.010 |
Why?
|
| Growth Hormone | 1 | 2000 | 130 | 0.010 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 1999 | 13 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2000 | 226 | 0.010 |
Why?
|
| Vital Capacity | 1 | 1980 | 81 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 1999 | 8 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2000 | 55 | 0.010 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 15 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 544 | 0.010 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1979 | 28 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 329 | 0.010 |
Why?
|
| Homovanillic Acid | 1 | 1979 | 30 | 0.010 |
Why?
|
| Temperature | 1 | 2000 | 291 | 0.010 |
Why?
|
| Electromyography | 1 | 1980 | 134 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1980 | 178 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 32 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2000 | 358 | 0.010 |
Why?
|
| Virus Replication | 1 | 2002 | 608 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 599 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1998 | 21 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 576 | 0.010 |
Why?
|
| Herpesvirus 2, Human | 1 | 1998 | 16 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2085 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1998 | 52 | 0.010 |
Why?
|
| Reflex, Abnormal | 1 | 1998 | 13 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 1211 | 0.010 |
Why?
|
| Urodynamics | 1 | 1998 | 34 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 509 | 0.010 |
Why?
|
| Phenylalanine | 1 | 1998 | 130 | 0.010 |
Why?
|
| Lysine | 1 | 1998 | 167 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2002 | 1445 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 1998 | 180 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 405 | 0.010 |
Why?
|
| Binding Sites | 1 | 1999 | 1133 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1928 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 2904 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 1997 | 174 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 2026 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1980 | 1626 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1997 | 419 | 0.010 |
Why?
|
| DNA | 1 | 1998 | 1399 | 0.010 |
Why?
|